FFO
TGTX icon

Fortitude Family Office’s TG Therapeutics TGTX Stock Holding History

Fortitude Family Office’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.01K Buy
+54
New +$2.92K ﹤0.01% 1821
2026
Q1 		– Sell
-8
Closed -$238 – 2073
2025
Q4 		$238 Buy
+8
New +$261 ﹤0.01% 1854

Other funds holding TGTX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return
AWM
Avaii Wealth Management Appleton, Wisconsin $348M AUM 25.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
CA
CWC Advisors Lake Oswego, Oregon $215M AUM 18.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
UWS
Unique Wealth Strategies Burr Ridge, Illinois $273M AUM 19.98% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Fortitude Family Office's TGTX Position: Q3 2026 in Review

Fortitude Family Office opened a new position in TG Therapeutics (TGTX) in Q3 2026: 54 shares worth $3.01K. The stake represents ﹤0.01% of the portfolio and ranks #1821 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in TGTX as recently as Q4 2025.

Fortitude Family Office first reported a position in TGTX in Q4 2025 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Fortitude Family Office held 54 shares of TG Therapeutics worth $3.01K as of Q3 2026.
  • TG Therapeutics was a new Fortitude Family Office position in Q3 2026.
  • TG Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1821 holding.
  • Fortitude Family Office first reported a position in TG Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.